Cellectis - Articles and news items

First patient treated in Phase I UCART19 trial in paediatric B-ALL

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL…

Servier exercises options to acquire worldwide rights to UCART19

Industry news / 19 November 2015 / Victoria White

Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia…

UCART19 used to treat ‘incurable’ leukaemia

Industry news / 6 November 2015 / Victoria White

A team at Great Ormond Street Hospital has used UCART 19 cells to treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia with positive results…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+